Evidence map›Paper›PMID 35989400›Full record

ReviewEuropean radiology experimental2022

The potential of predictive and prognostic breast MRI (P2-bMRI).

Matthias Dietzel, Rubina Manuela Trimboli, Moreno Zanardo, Rüdiger Schultz-Wendtland, Michael Uder, Paola Clauser, Francesco Sardanelli, Pascal A T Baltzer

Open access · goldAbstract readReview
In one paragraph

Review in European radiology experimental, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Recent nanotheranostic approaches in cancer research.Clinical and experimental medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Matthias DietzelDepartment of Radiology, University Hospital Erlangen, Maximiliansplatz 3, 91054, Erlangen, Germany.ORCID 0000-0001-9248-1398
Rubina Manuela TrimboliHumanitas Clinical and Research Center - IRCCS, Via Manzoni 56, Rozzano, Milan, Italy.
Moreno ZanardoDepartment of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133, Milan, Italy.
Rüdiger Schultz-WendtlandDepartment of Radiology, University Hospital Erlangen, Maximiliansplatz 3, 91054, Erlangen, Germany.
Michael UderDepartment of Radiology, University Hospital Erlangen, Maximiliansplatz 3, 91054, Erlangen, Germany.
Paola ClauserDivision of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Waehringer-Guertel, 18-20, Vienna, Austria.
Francesco Sardanelli *Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133, Milan, Italy. francesco.sardanelli@unimi.it.
Pascal A T Baltzer *Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Waehringer-Guertel, 18-20, Vienna, Austria. pascal.baltzer@meduniwien.ac.at.ORCID 0000-0002-3755-5398
Universitätsklinikum Erlangen · DEMedical University of Vienna · ATUniversity of Milan · ITHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic resonance imaging (MRI) is an important part of breast cancer diagnosis and multimodal workup. It provides unsurpassed soft tissue contrast to analyse the underlying pathophysiology, and it is adopted for a variety of clinical indications. Predictive and prognostic breast MRI (P2-bMRI) is an emerging application next to these indications. The general objective of P2-bMRI is to provide predictive and/or prognostic biomarkers in order to support personalisation of breast cancer treatment. We believe P2-bMRI has a great clinical potential, thanks to the in vivo examination of the whole tumour and of the surrounding tissue, establishing a link between pathophysiology and response to therapy (prediction) as well as patient outcome (prognostication). The tools used for P2-bMRI cover a wide spectrum: standard and advanced multiparametric pulse sequences; structured reporting criteria (for instance BI-RADS descriptors); artificial intelligence methods, including machine learning (with emphasis on radiomics data analysis); and deep learning that have shown compelling potential for this purpose. P2-bMRI reuses the imaging data of examinations performed in the current practice. Accordingly, P2-bMRI could optimise clinical workflow, enabling cost savings and ultimately improving personalisation of treatment. This review introduces the concept of P2-bMRI, focusing on the clinical application of P2-bMRI by using semantic criteria.

Indexed as

Artificial IntelligenceBreast NeoplasmsBreastFemaleHumansMagnetic Resonance ImagingPrognosisBiomarkersBreast neoplasmsMagnetic resonance imagingPrecision medicinePrognosis

Identifiers

PMID35989400
PMCPMC9393116
OpenAlexW4292688145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.